Preparation and Optimization of Liposome Containing Thermosensitive In Situ Nasal Hydrogel System for Brain Delivery of Sumatriptan Succinate
Drug absorption is improved by the intranasal route's wide surface area and avoidance of first-pass metabolism. For the treatment of central nervous system diseases such as migraine, intranasal administration delivers the medication to the brain. The study's purpose was to develop an in situ nasal hydrogel that contained liposomes that were loaded with sumatriptan succinate (SS). A thin-film hydration approach was used to create liposomes, and a 32 factorial design was used to optimize them. The optimized liposomes had a spherical shape, a 171.31 nm particle size, a high drug encapsulation efficiency of 83.54%, and an 8-h drug release of 86.11%. To achieve in situ gel formation, SS-loaded liposomes were added to the liquid gelling system of poloxamer-407, poloxamer-188, and sodium alginate. The final product was tested for mucoadhesive strength, viscosity, drug content, gelation temperature, and gelation time. Following intranasal delivery, in vivo pharmacokinetic investigations showed a significant therapeutic concentration of the medication in the brain with a Cmax value of 167 ± 78 ng/mL and an area under the curve value of 502 ± 63 ng/min·mL. For SS-loaded liposomal thermosensitive nasal hydrogel, significantly higher values of the nose-to-brain targeting parameters, that is, drug targeting index (2.61) and nose-to-brain drug direct transport (57.01%), confirmed drug targeting to the brain through the nasal route. Liposomes containing thermosensitive in situ hydrogel demonstrated potential for intranasal administration of SS.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
---|---|
Enthalten in: |
Assay and drug development technologies - 21(2023), 1 vom: 28. Jan., Seite 3-16 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Mathure, Dyandevi [VerfasserIn] |
---|
Links: |
---|
Themen: |
106392-12-5 |
---|
Anmerkungen: |
Date Completed 19.01.2023 Date Revised 16.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1089/adt.2022.088 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM350882665 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM350882665 | ||
003 | DE-627 | ||
005 | 20231226050009.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1089/adt.2022.088 |2 doi | |
028 | 5 | 2 | |a pubmed24n1169.xml |
035 | |a (DE-627)NLM350882665 | ||
035 | |a (NLM)36576871 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Mathure, Dyandevi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Preparation and Optimization of Liposome Containing Thermosensitive In Situ Nasal Hydrogel System for Brain Delivery of Sumatriptan Succinate |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 19.01.2023 | ||
500 | |a Date Revised 16.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Drug absorption is improved by the intranasal route's wide surface area and avoidance of first-pass metabolism. For the treatment of central nervous system diseases such as migraine, intranasal administration delivers the medication to the brain. The study's purpose was to develop an in situ nasal hydrogel that contained liposomes that were loaded with sumatriptan succinate (SS). A thin-film hydration approach was used to create liposomes, and a 32 factorial design was used to optimize them. The optimized liposomes had a spherical shape, a 171.31 nm particle size, a high drug encapsulation efficiency of 83.54%, and an 8-h drug release of 86.11%. To achieve in situ gel formation, SS-loaded liposomes were added to the liquid gelling system of poloxamer-407, poloxamer-188, and sodium alginate. The final product was tested for mucoadhesive strength, viscosity, drug content, gelation temperature, and gelation time. Following intranasal delivery, in vivo pharmacokinetic investigations showed a significant therapeutic concentration of the medication in the brain with a Cmax value of 167 ± 78 ng/mL and an area under the curve value of 502 ± 63 ng/min·mL. For SS-loaded liposomal thermosensitive nasal hydrogel, significantly higher values of the nose-to-brain targeting parameters, that is, drug targeting index (2.61) and nose-to-brain drug direct transport (57.01%), confirmed drug targeting to the brain through the nasal route. Liposomes containing thermosensitive in situ hydrogel demonstrated potential for intranasal administration of SS | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a brain delivery | |
650 | 4 | |a drug delivery | |
650 | 4 | |a in situ nasal gel | |
650 | 4 | |a liposome | |
650 | 4 | |a thermosensitive hydrogel | |
650 | 7 | |a Liposomes |2 NLM | |
650 | 7 | |a Sumatriptan |2 NLM | |
650 | 7 | |a 8R78F6L9VO |2 NLM | |
650 | 7 | |a Hydrogels |2 NLM | |
650 | 7 | |a Poloxamer |2 NLM | |
650 | 7 | |a 106392-12-5 |2 NLM | |
700 | 1 | |a Sutar, Ashish Dilip |e verfasserin |4 aut | |
700 | 1 | |a Ranpise, Hemantkumar |e verfasserin |4 aut | |
700 | 1 | |a Pawar, Atmaram |e verfasserin |4 aut | |
700 | 1 | |a Awasthi, Rajendra |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Assay and drug development technologies |d 2002 |g 21(2023), 1 vom: 28. Jan., Seite 3-16 |w (DE-627)NLM14784164X |x 1557-8127 |7 nnns |
773 | 1 | 8 | |g volume:21 |g year:2023 |g number:1 |g day:28 |g month:01 |g pages:3-16 |
856 | 4 | 0 | |u http://dx.doi.org/10.1089/adt.2022.088 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 21 |j 2023 |e 1 |b 28 |c 01 |h 3-16 |